LENZ Therapeutics, Inc. (LENZ) Institutional Ownership

Ownership Summary

The institutional landscape for LENZ Therapeutics, Inc. (NASDAQ:LENZ) includes 164 filers as of the latest reporting cycle ending September 2025.

• LENZ Therapeutics saw its institutional ownership percentage rose to 102.1% in September 2025 from 88.6% in June 2025.
• The company experienced a 22.97% quarterly change in institutional shares held, alongside an increase of 112.99% in total owners annually.
• Among the 164 institutional holders of LENZ Therapeutics, 115 added to their stakes while 27 trimmed their positions and 22 held steady.
• The aggregate institutional position in LENZ Therapeutics now stands at 29.12Mn shares as of September 2025, after investors increased their holdings (up by 5.44Mn shares quarter on quarter which is up 10.41Mn shares year over year).
• The top institutional stake in LENZ Therapeutics as of September 30, 2025 belongs to RA CAPITAL MANAGEMENT, L.P., which owns 4.18Mn shares, or 14.65% of the company.
• Among the most significant buyers of LENZ Therapeutics during September 2025 were Versant Venture Management, LLC (2.66Mn), First Light Asset Management, LLC (693.04K), FRANKLIN RESOURCES INC (578.52K), CITADEL ADVISORS LLC (389.84K), UBS Group AG (320.13K).
• Leading sellers of LENZ Therapeutics stock in September 2025 included Paradigm Biocapital Advisors LP (643.61K), ADAGE CAPITAL PARTNERS GP, L.L.C. (495.12K), MORGAN STANLEY (289.14K), Point72 Asset Management, L.P. (278.14K), Ally Bridge Group (NY) LLC (167.96K).
• The top 10 institutional holders of LENZ Therapeutics for the quarter ending September 2025 included RA CAPITAL MANAGEMENT, L.P. (4.18Mn), Alpha Wave Global, LP (3.61Mn), Versant Venture Management, LLC (2.66Mn), BlackRock, Inc. (1.47Mn), VANGUARD GROUP INC (1.33Mn), UBS Group AG (1.20Mn), Paradigm Biocapital Advisors LP (1.07Mn), 72 Investment Holdings, LLC (1.02Mn), TANG CAPITAL MANAGEMENT LLC (897.62K), RTW INVESTMENTS, LP (863.39K).